TYRO3 belongs to the TAM (TYRO3, AXL, and MER) receptor family, a unique subfamily of the receptor tyrosine kinases. Members of TAM family share the same ligand, growth arrest-specific 6, and protein S. Although the signal transduction pathways of TYRO3 have not been evaluated in detail, overexpression and activation of TYRO3 receptor tyrosine kinase have been reported to promote cell proliferation, survival, tumorigenesis, migration, invasion, epithelial-mesenchymal transition, or chemoresistance in several human cancers. Targeting TYRO3 could break the kinase signaling, stimulate antitumor immunity, reduce tumor cell survival, and regain drug sensitivity. To date, there is no specific TYRO3-targeted drug, the effectiveness of targeting TYRO3 in cancer is worthy of further investigations. In this review, we present an update on molecular biology of TYRO3, summarize the development of potential inhibitors of TAM family members, and provide new insights in TYRO3-targeted treatment.
Impact statement
Cancer is among the leading causes of death worldwide. In 2016, 8.9 million people are estimated to have died from various forms of cancer. The current treatments, including surgery with chemotherapy and/or radiation therapy, are not effective enough to provide full protection from cancer, which highlights the need for developing novel therapy strategies. In this review, we summarize the molecular biology of a unique member of a subfamily of receptor tyrosine kinase, TYRO3 and discuss the new insights in TYRO3-targeted treatment for cancer therapy.
VouriMHafiziS.TAM receptor tyrosine kinases in cancer drug resistance. Cancer Res2017;
77:2775–8
2.
LaiCLemkeG.An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron1991;
6:691–704
3.
GoudarziSRiveraAButtAMHafiziS.Gas6 promotes oligodendrogenesis and myelination in the adult central nervous system and after lysolecithin-induced demyelination. ASN Neuro2016;
8:1–14
4.
TaylorICRoySVarmusHE.Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation. Oncogene1995;
11:2619–26
5.
CrosierPSLewisPMHallLRVitasMRMorrisCMBeierDRWoodCRCrosierKE.Isolation of a receptor tyrosine kinase (DTK) from embryonic stem cells: structure, genetic mapping and analysis of expression. Growth Factors1994;
11:125–36
6.
FujimotoJYamamotoT.brt, a mouse gene encoding a novel receptor-type protein-tyrosine kinase, is preferentially expressed in the brain. Oncogene1994;
9:693–8
7.
MarkMRScaddenDTWangZGuQGoddardAGodowskiPJ.rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J Biol Chem1994;
269:10720–8
8.
LaiCGoreMLemkeG.Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene1994;
9:2567–78
9.
OhashiKMizunoKKumaKMiyataTNakamuraT.Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene1994;
9:699–705
10.
DaiWPanHHassanainHGuptaSLMurphyMJJr.Molecular cloning of a novel receptor tyrosine kinase, tif, highly expressed in human ovary and testis. Oncogene1994;
9:975–9
11.
LewisPMCrosierKEWoodCRCrosierPS.Analysis of the murine Dtk gene identifies conservation of genomic structure within a new receptor tyrosine kinase subfamily. Genomics1996;
31:13–9
12.
BieseckerLGGiannolaDMEmersonSG.Identification of alternative exons, including a novel exon, in the tyrosine kinase receptor gene Etk2/tyro3 that explain differences in 5' cDNA sequences. Oncogene1995;
10:2239–42
13.
LuQGoreMZhangQCamenischTBoastSCasagrandaFLaiCSkinnerMKKleinRMatsushimaGKEarpHSGoffSPLemkeG.Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature1999;
398:723–8
14.
MarkMRChenJHammondsRGSadickMGodowskPJ.Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem1996;
271:9785–9
15.
SasakiTKnyazevPGCheburkinYGohringWTisiDUllrichATimplRHohenesterE.Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains. J Biol Chem2002;
277:44164–70
16.
StittTNConnGGoreMLaiCBrunoJRadziejewskiCMattssonKFisherJGiesDRJonesPFMasiakowskiPRyanTETobkesNJChenDHDiStefanoPSLongGLBasilicoCGoldfarbMPLemkeGGlassDJYancopoulosGD.The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell1995;
80:661–70
17.
PrasadDRothlinCVBurrolaPBurstyn-CohenTLuQGarcia de FrutosPLemkeG.TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci2006;
33:96–108
18.
ManfiolettiGBrancoliniCAvanziGSchneiderC.The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol1993;
13:4976–85
19.
SchneiderCKingRMPhilipsonL.Genes specifically expressed at growth arrest of mammalian cells. Cell1988;
54:787–93
20.
VarnumBCYoungCElliottGGarciaABartleyTDFridellYWHuntRWTrailGClogstonCTosoRJYanagiharaDBennettLSylberMMerewetherLATsengAEscobarELiuETYamaneHK.Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature1995;
373:623–6
21.
NagataKOhashiKNakanoTAritaHZongCHanafusaHMizunoK.Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem1996;
271:30022–7
22.
HuangMRigbyACMorelliXGrantMAHuangGFurieBSeatonBFurieBC.Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Mol Biol2003;
10:751–6
23.
TsouWINguyenKQCalareseDAGarforthSJAntesALSmirnovSVAlmoSCBirgeRBKotenkoSV.Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem2014;
289:25750–63
24.
LewEDOhJBurrolaPGLaxIZagorskaATravesPGSchlessingerJLemkeG.Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. eLife2014;
3:e03385
25.
TodtJCHuBCurtisJL.The receptor tyrosine kinase MerTK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages. J Leukoc Biol2004;
75:705–13
26.
LiRChenJHammondsGPhillipsHArmaniniMWoodPBungeRGodowskiPJSliwkowskiMXMatherJP.Identification of Gas6 as a growth factor for human Schwann cells. J Neurosci1996;
16:2012–9
27.
FridellYWJinYQuilliamLABurchertAMcCloskeyPSpizzGVarnumBDerCLiuET.Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol1996;
16:135–45
28.
CaberoyNBZhouYLiW.Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis. EMBO J2010;
29:3898–910
29.
LemkeGRothlinCV.Immunobiology of the TAM receptors. Nat Rev Immunol2008;
8:327–36
30.
IkedaSHeWIkedaANaggertJKNorthMANishinaPM.Cell-specific expression of tubby gene family members (tub, Tulp1,2, and 3) in the retina. Invest Ophthalmol Vis Sci1999;
40:2706–12
31.
NickelWSeedorfM.Unconventional mechanisms of protein transport to the cell surface of eukaryotic cells. Annu Rev Cell Dev Biol2008;
24:287–308
32.
CaberoyNBLiW.Unconventional secretion of tubby and tubby-like protein 1. FEBS Lett2009;
583:3057–62
33.
LemkeG.Biology of the TAM receptors. Cold Spring Harb Perspect Biol2013;
5:a009076
34.
PierceABliesnerBXuMNielsen-PreissSLemkeGTobetSWiermanME.Axl and Tyro3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration. Mol Endocrinol2008;
22:2481–95
35.
LuQLemkeG.Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science2001;
293:306–11
36.
Angelillo-ScherrerAde FrutosPAparicioCMelisESaviPLupuFArnoutJDewerchinMHoylaertsMHerbertJCollenDDahlbackBCarmelietP.Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med2001;
7:215–21
37.
Angelillo-ScherrerABurnierLFloresNSaviPDeMolMSchaefferPHerbertJMLemkeGGoffSPMatsushimaGKEarpHSVesinCHoylaertsMFPlaisanceSCollenDConwayEMWehrle-HallerBCarmelietP.Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest2005;
115:237–46
38.
FujitaKChenXHommaHTagawaKAmanoMSaitoAImotoSAkatsuHHashizumeYKaibuchiKMiyanoSOkazawaH.Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. Nat Commun2018;
9:433
39.
ChanPYCarrera SilvaEADe KouchkovskyDJoannasLDHaoLHuDHuntsmanSEngCLicona-LimonPWeinsteinJSHerbertDRCraftJEFlavellRARepettoSCorrealeJBurchardEGTorgersonDGGhoshSRothlinCV.The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity. Science2016;
352:99–103
40.
KimDYYuJMuiRKNiiboriRTaufiqueHBAslamRSempleJWCordesSP.The tyrosine kinase receptor Tyro3 enhances lifespan and neuropeptide Y (Npy) neuron survival in the mouse anorexia (anx) mutation. Dis Model Mech2017;
10:581–95
41.
TaylorICRoySYaswenPStampferMRVarmusHE.Mouse mammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase. J Biol Chem1995;
270:6872–80
42.
CrosierPSHallLRVitasMRLewisPMCrosierKE.Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leuk Lymphoma1995;
18:443–9
43.
AvillaEGuarinoVViscianoCLiottiFSveltoMKrishnamoorthyGFrancoRMelilloRM.Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res2011;
71:1792–804
44.
ShaoHWangALauffenburgerDWellsA.Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain. Int J Biochem Cell Biol2018;
95:73–84
45.
KabirTDGandaCBrownRMBeveridgeDJRichardsonKLChaturvediVCandyPEpisMWintleLKalinowskiFKoppCStuartLMYeohGCGeorgeJLeedmanPJ.A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology2018;
67:216–31
46.
SchmitzRVallsAFYerbesRvon RichterSKahlertCLogesSWeitzJSchneiderMde AlmodovarCRUlrichASchmidtT.TAM receptors Tyro3 and Mer as novel targets in colorectal cancer. Oncotarget2016;
7:56355–70
47.
LeeC.Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells. Mol Med Rep2015;
12:1485–92
48.
ChienCWHouPCWuHCChangYLLinSCLinSCLinBWLeeJCChangYJSunHSTsaiSJ.Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. Oncogene2016;
35:5872–81
49.
DemarestSJGardnerJVendelMCAilorESzakSHuangFDoernATanXYangWGruenebergDARichardsEJEndegeWOHarlowEKoopmanLA.Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines. Biochemistry2013;
52:3102–18
50.
Dantas-BarbosaCLesluyesTLoarerFLChibonFTreilleuxICoindreJMMeeusPBrahmiMBallyORay-CoquardISunyachMPCesneALMirOBonvalotSToulmondeMItalianoASaintignyPJean-DenisMDucimetiereFRanchereDEl SayadiHAlbertiLBlayJY.Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. Br J Cancer2017;
117:1787–97
51.
ChengCLHouHALeeMCLiuCYJhuangJYLaiYJLinCWChenHYLiuFTChouWCChenCYTangJLYaoMHuangSYKoBSWuSJTsayWTienHF.Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood2013;
121:3172–80
52.
De VosJCoudercGTarteKJourdanMRequirandGDelteilMCRossiJFMechtiNKleinB.Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood2001;
98:771–80
53.
WimmelARohnerIRamaswamyAHeidtmannHHSeitzRKrausMSchuermannM.Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer1999;
86:43–9
54.
RikovaKGuoAZengQPossematoAYuJHaackHNardoneJLeeKReevesCLiYHuYTanZStokesMSullivanLMitchellJWetzelRMacneillJRenJMYuanJBakalarskiCEVillenJKornhauserJMSmithBLiDZhouXGygiSPGuTLPolakiewiczRDRushJCombMJ.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell2007;
131:1190–203
55.
TworkoskiKSinghalGSzpakowskiSZitoCIBacchiocchiAMuthusamyVBosenbergMKrauthammerMHalabanRSternDF.Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res2011;
9:801–12
56.
ZhuSWurdakHWangYGalkinATaoHLiJLyssiotisCAYanFTuBPMiragliaLWalkerJSunFOrthASchultzPGWuX.A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A2009;
106:17025–30
57.
ShiozawaYPedersenEAPatelLRZieglerAMHavensAMJungYWangJZaluchaSLobergRDPientaKJTaichmanRS.GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia2010;
12:116–27
58.
SunWSFujimotoJTamayaT.Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann Oncol2003;
14:898–906
59.
AmmounSProvenzanoLZhouLBarczykMEvansKHiltonDAHafiziSHanemannCO.Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene2014;
33:336–46
60.
DuanYWongWChuaSCWeeHLLimSGChuaBTHoHK.Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression. Int J Oncol2016;
48:358–66
61.
Qin A,QianW.MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression. Int J Mol Med2018;
42:2503–14
62.
NemotoTOhashiKAkashiTJohnsonJDHirokawaK.Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology1997;
65:195–203
63.
ThomsonSPettiFSujka-KwokIMercadoPBeanJMonaghanMSeymourSLArgastGMEpsteinDMHaleyJD.A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastas2011;
28:137–55
64.
JansenFHvan RijswijkATeubelWvan WeerdenWMRenemanSvan den BemdGJRoobolMJBangmaCHStaalFJJensterG.Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers. J Proteome Res2012;
11:728–35
65.
AlexanderPBChenRGongCYuanLJasperJSDingYMarkowitzGJYangPXuXMcDonnellDPSongEWangXF.Distinct receptor tyrosine kinase subsets mediate anti-HER2 drug resistance in breast cancer. J Biol Chem2017;
292:748–59
66.
KasikaraCKumarSKimaniSTsouWIGengKDavraVSriramGDevoeCNguyenKNAntesAKrantzARymarczykGWilczynskiAEmpigCFreimarkBGrayMSchluneggerKHutchinsJKotenkoSVBirgeRB.Phosphatidylserine sensing by TAM receptors regulates AKT-dependent chemoresistance and PD-L1 expression. Mol Cancer Res2017;
15:753–64
67.
TaichmanRSPatelLRBedenisRWangJWeidnerSSchumannTYumotoKBerryJEShiozawaYPientaKJ.GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One2013;
8:e61873
68.
AmmounSCunliffeCHAllenJCChiribogaLGiancottiFGZagzagDHanemannCOKarajannisMA.ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neurooncology2010;
12:834–43
69.
SinhaSBoysenJNelsonMSecretoCWarnerSLBearssDJLesnickCShanafeltTDKayNEGhoshAK.Targeted Axl inhibition primes chronic lymphocytic leukemia B Cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors. Clin Cancer Res2015;
21:2115–26
70.
NeubauerABurchertAMaiwaldCGrussHJSerkeSHuhnDWittigBLiuE.Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Leuk Lymphoma1997;
25:91–6
71.
GhoshAKSecretoCBoysenJSassoonTShanafeltTDMukhopadhyayDKayNE.The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood2011;
117:1928–37
72.
WimmelAGlitzDKrausARoederJSchuermannM.Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer2001;
37:2264–74
73.
KeatingAKKimGKJonesAEDonsonAMWareKMulcahyJMSalzbergDBForemanNKLiangXThorburnAGrahamDK.Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther2010;
9:1298–307
74.
ZhangYXKnyazevPGCheburkinYVSharmaKKnyazevYPOrfiLSzabadkaiIDaubHKeriGUllrichA.AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res2008;
68:1905–15
75.
CravenRJXuLHWeinerTMFridellYWDentGASrivastavaSVarnumBLiuETCanceWG.Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer1995;
60:791–7
76.
MudduluruGVajkoczyPAllgayerH.Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res2010;
8:159–69
77.
LinWCLiAFChiCWChungWWHuangCLLuiWYKungHJWuCW.tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res1999;
5:1745–51
78.
SawabuTSenoHKawashimaTFukudaAUenoyamaYKawadaMKandaNSekikawaAFukuiHYanagitaMYoshibayashiHSatohSSakaiYNakanoTChibaT.Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog2007;
46:155–64
79.
SongXWangHLogsdonCDRashidAFlemingJBAbbruzzeseJLGomezHFEvansDBWangH.Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer2011;
117:734–43
80.
LeconetWLarbouretCChardesTThomasGNeiveyansMBussonMJarlierMRadosevic-RobinNPugniereMBernexFPenault-LlorcaFPasquetJMPelegrinARobertB.Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene2014;
33:5405–14
81.
HectorAMontgomeryEAKarikariCCantoMDunbarKBWangJSFeldmannGHongSMHaffnerMCMeekerAKHollandSJYuJHeckrodtTJZhangJDingPGoffDSinghRRoaJCMarimuthuARigginsGJEshlemanJRNelkinBDPandeyAMaitraA.The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther2010;
10:1009–18
82.
van GinkelPRGeeRLShearerRLSubramanianLWalkerTMAlbertDMMeisnerLFVarnumBCPolansAS.Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res2004;
64:128–34
83.
TworkoskiKAPlattJTBacchiocchiABosenbergMBoggonTJSternDF.MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res2013;
26:527–41
84.
GreenJIkramMVyasJPatelNProbyCMGhaliLLeighIMO'TooleEAStoreyA.Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer2006;
94:1446–51
85.
PaccezJDVasquesGJCorreaRGVasconcellosJFDuncanKGuXBhasinMLibermannTAZerbiniLF.The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene2013;
32:689–98
86.
SunWFujimotoJTamayaT.Coexpression of Gas6/Axl in human ovarian cancers. Oncology2004;
66:450–7
87.
ChenPXLiQYYangZ.Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann Diagn Pathol2013;
17:425–9
88.
RankinEBFuhKCTaylorTEKriegAJMusserMYuanJWeiKKuoCJLongacreTAGiacciaAJ.AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res2010;
70:7570–9
89.
LeeCHYenCYLiuSYChenCKChiangCFShiahSGChenPHShiehYS.Axl is a prognostic marker in oral squamous cell carcinoma. Ann Surg Oncol2012;
19:S500–8
90.
YehCYShinSMYehHHWuTJShinJWChangTYRaghavarajuGLeeCTChiangJHTsengVSLeeYCShenCHChowNHLiuHS.Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer2011;
11:139
91.
GustafssonAMartuszewskaDJohanssonMEkmanCHafiziSLjungbergBDahlbackB.Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res2009;
15:4742–9
92.
OuWBCorsonJMFlynnDLLuWPWiseSCBuenoRSugarbakerDJFletcherJA.AXL regulates mesothelioma proliferation and invasiveness. Oncogene2011;
30:1643–52
93.
LiuRGongMLiXZhouYGaoWTulpuleAChaudharyPMJungJGillPS.Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood2010;
116:297–305
94.
IshikawaMSonobeMNakayamaEKobayashiMKikuchiRKitamuraJImamuraNDateH.Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol2013;
20:S467–76
95.
GilesKMKalinowskiFCCandyPAEpisMRZhangPMRedfernADStuartLMGoodallGJLeedmanPJ.Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther2013;
12:2541–58
96.
HanJTianRYongBLuoCTanPShenJPengT.Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun2013;
435:493–500
97.
WuCWLiAFChiCWLaiCHHuangCLLoSSLuiWYLinWC.Clinical significance of AXL kinase family in gastric cancer. Anticancer Res2002;
22:1071–8
98.
JiaoYOuWMengFZhouHWangA.Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer2011;
10:125
99.
ZhaoYSunXJiangLYangFZhangZJiaL.Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells. Cancer Invest2012;
30:287–94
100.
LiYYeXTanCHongoJAZhaJLiuJKallopDLudlamMJPeiL.Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene2009;
28:3442–55
101.
HeLZhangJJiangLJinCZhaoYYangGJiaL.Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol Carcinog2010;
49:882–91
102.
RettewANYoungEDLevDCKleinermanESAbdul-KarimFWGettyPJGreenfieldEM.Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis2012;
1:e34
103.
HollandSJPowellMJFranciCChanEWFrieraAMAtchisonREMcLaughlinJSwiftSEPaliESYamGWongSLasagaJShenMRYuSXuWHitoshiYBogenbergerJNorJEPayanDGLorensJB.Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res2005;
65:9294–303
104.
MishraAWangJShiozawaYMcGeeSKimJJungYJosephJBerryJEHavensAPientaKJTaichmanRS.Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol Cancer Res2012;
10:703–12
105.
SayanAEStanfordRVickeryRGrigorenkoEDieschJKulbickiKEdwardsRPalRGreavesPJariel-EncontreIPiechaczykMKriajevskaMMellonJKDhillonASTulchinskyE.Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene2012;
31:1493–503
106.
DuijkersFAMeijerinkJPPietersRvan NoeselMM.Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration. Gene2013;
521:62–8
107.
HongCCLayJDHuangJSChengALTangJLLinMTLaiGMChuangSE.Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett2008;
268:314–24
108.
LayJDHongCCHuangJSYangYYPaoCYLiuCHLaiYPLaiGMChengALSuIJChuangSE.Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res2007;
67:3878–87
109.
HongJPengDChenZSehdevVBelkhiriA.ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res2013;
73:331–40
110.
LingerRMCohenRACummingsCTSatherSMigdall-WilsonJMiddletonDHLuXBaronAEFranklinWAMerrickDTJedlickaPDeRyckereDHeasleyLEGrahamDK.Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene2013;
32:3420–31
111.
Lee-SherickABEisenmanKMSatherSMcGranahanAArmisteadPMMcGaryCSHunsuckerSASchlegelJMartinsonHCannonCKeatingAKEarpHSLiangXDeRyckereDGrahamDK.Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene2013;
32:5359–68
112.
GrahamDKDawsonTLMullaneyDLSnodgrassHREarpHS.Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Different1994;
5:647–57
113.
BrandaoLNWingesAChristophSSatherSMigdall-WilsonJSchlegelJMcGranahanAGaoDLiangXDeryckereDGrahamDK.Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J2013;
3:e101
114.
WangYMoncayoGMorinPJr.XueGGrzmilMLinoMMClement-SchatloVFrankSMerloAHemmingsBA.Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene2013;
32:872–82
115.
SchlegelJSambadeMJSatherSMoschosSJTanACWingesADeRyckereDCarsonCCTrembathDGTentlerJJEckhardtSGKuanPFHamiltonRLDuncanLMMillerCRNikolaishvili-FeinbergNMidkiffBRLiuJZhangWYangCWangXFryeSVEarpHSShieldsJMGrahamDK.MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest2013;
123:2257–67
116.
WuYMRobinsonDRKungHJ.Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res2004;
64:7311–20
117.
EkSHogerkorpCMDictorMEhingerM.Borrebaeck C A Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res2002;
62:4398–405
118.
KnubelKHPernuBMSufitANelsonSPierceAMKeatingAK.MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget2014;
5:1338–51
119.
DirksWRomeDRingelFJagerKMacLeodRADrexlerHG.Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk Res1999;
23:643–51
120.
HuttererMKnyazevPAbateAReschkeMMaierHStefanovaNKnyazevaTBarbieriVReindlMMuiggAKostronHStockhammerGUllrichA.Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res2008;
14:130–8
121.
Mc CormackOChungWYFitzpatrickPCookeFFlynnBHarrisonMFoxEGallagherEGoldrickAMDervanPAMc CannAKerinMJ.Growth arrest-specific gene 6 expression in human breast cancer. Br J Cancer2008;
98:1141–6
122.
BuehlerMTseBLeboucqAJacobFCaduffRFinkDGoldsteinDRHeinzelmann-SchwarzV.Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. Biomed Res Int2013;
2013:238284
123.
ItoMNakashimaMNakayamaTOhtsuruANagayamaYTakamuraNDemedchikEPSekineIYamashitaS.Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl. Thyroid2002;
12:971–5
124.
WhitmanSPKohlschmidtJMaharryKVoliniaSMrozekKNicoletDSchwindSBeckerHMetzelerKHMendlerJHEisfeldAKCarrollAJPowellBLCarterTHBaerMRKolitzJEParkIKStoneRMCaligiuriMAMarcucciGBloomfieldCD.GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia2014;
28:1252–8
125.
LogesSSchmidtTTjwaMvan GeyteKLievensDLutgensEVanhoutteDBorgelDPlaisanceSHoylaertsMLuttunADewerchinMJonckxBCarmelietP.Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood2010;
115:2264–73
126.
SainaghiPPCastelloLBergamascoLGallettiMBellostaPAvanziGC.Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol2005;
204:36–44
127.
GustafssonABostromAKLjungbergBAxelsonHDahlbackB.Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One2009;
4:e7575
128.
LeeYLeeMKimS.Gas6 induces cancer cell migration and epithelial-mesenchymal transition through upregulation of MAPK and Slug. Biochem Biophys Res Commun2013;
434:8–14
129.
ShiozawaYPedersenEATaichmanRS.GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp Hematol2010;
38:132–40
130.
AbeAEmiNKatoHAdachiKMurateTSagaSOguraMKojimaTTanimotoMMorishitaN.
Establishment and characterization of an immature human megakaryoblastic cell line, MEG-A2. Leukemia1995;
9:341–9
131.
ChungKWKimSWKimSW.Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays. J Korean Surg Soc2012;
82:271–80
132.
GriffithOLMelckAJonesSJWisemanSM.Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol2006;
24:5043–51
133.
SierkoEWojtukiewiczMZZawadzkiRZimnochLKisielW.Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. Thromb Res2010;
125:e71–5
134.
PuttermanCTadmorBSimerLCaracoY.Recurrent venous thrombosis as the presenting sign of two primary lung carcinomas – 15 years apart. Respir Med1992;
86:521–3
135.
PhillipsDJGreengardJSFernandezJARibeiroMEvattBLGriffinJHHooperWC.Protein S, an antithrombotic factor, is synthesized and released by neural tumor cells. J Neurochem1993;
61:344–7
136.
WojtukiewiczMZZacharskiLRMemoliVAKisielWKudrykBJRousseauSMStumpDC.Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer1990;
65:481–5
137.
SaraonPMusrapNCretuDKaragiannisGSBatruchISmithCDrabovichAPTrudelDvan der KwastTMorrisseyCJarviKADiamandisEP.Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. J Biol Chem2012;
287:34019–31
138.
FacaVMVenturaAPFitzgibbonMPPereira-FacaSRPitteriSJGreenAEIretonRCZhangQWangHO'BriantKCDrescherCWSchummerMMcIntoshMWKnudsenBSHanashSM.Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One2008;
3:e2425
139.
MaillardCBerruyerMSerreCMDechavanneMDelmasPD.Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology1992;
130:1599–604
140.
Che MatMFAbdul MuradNAIbrahimKMohd MokhtarNWan NgahWZHarunRJamalR.Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells. Int J Oncol2016;
49:2359–66
141.
NingPZhongJGJiangFZhangYZhaoJTianFLiW.Role of protein S in castration-resistant prostate cancer-like cells. Endocrine Relat Cancer2016;
23:595–607
142.
EkyalongoRCMukoharaTFunakoshiYTomiokaHKataokaYShimonoYChayaharaNToyodaMKiyotaNMinamiH.TYRO3 as a potential therapeutic target in breast cancer. Anticancer Res2014;
34:3337–45
143.
ChungJHRhoJKXuXLeeJSYoonHILeeCTChoiYJKimHRKimCHLeeJC. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer2011;
73:176–82
144.
SequistLVWaltmanBADias-SantagataDDigumarthySTurkeABFidiasPBergethonKShawATGettingerSCosperAKAkhavanfardSHeistRSTemelJChristensenJGWainJCLynchTJVernovskyKMarkEJLanutiMIafrateAJMino-KenudsonMEngelmanJA.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med2011;
3:75ra26
145.
LiuYZengG.Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother2012;
35:299–308
146.
ToshimaJOhashiKIwashitaSMizunoK.Autophosphorylation activity and association with Src family kinase of Sky receptor tyrosine kinase. Biochem Biophys Res Commun1995;
209:656–63
147.
LanZWuHLiWWuSLuLXuMDaiW.Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood2000;
95:633–8
148.
HafiziSGustafssonAStenhoffJDahlbackB.The Ran binding protein RanBPM interacts with Axl and Sky receptor tyrosine kinases. Int J Biochem Cell Biol2005;
37:2344–56
149.
GuoHBarrettTMZhongZFernandezJAGriffinJHFreemanRSZlokovicBV.Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener2011;
6:13
150.
ZhongZWangYGuoHSagareAFernandezJABellRDBarrettTMGriffinJHFreemanRSZlokovicBV.Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci2010;
30:15521–34
151.
ChenJCareyKGodowskiPJ.Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene1997;
14:2033–9
152.
KatagiriMHakedaYChikazuDOgasawaraTTakatoTKumegawaMNakamuraKKawaguchiH.Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol Chem2001;
276:7376–82
153.
EkyalongoRCMukoharaTKataokaYFunakoshiYTomiokaHKiyotaNFujiwaraYMinamiH.Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Invest New Drugs2013;
31:293–303
154.
IrieHBannoKYanokuraMIidaMAdachiMNakamuraKUmeneKNogamiYMasudaKKobayashiYTominagaEAokiD.Metformin: a candidate for the treatment of gynecological tumors based on drug repositioning. Oncol Lett2016;
11:1287–93
155.
KimNYLeeHYLeeC.Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. Int J Oncol2015;
47:353–60
156.
PowellNAHoffmanJKCiskeFLKohrtJTBaxiSMPengYWZhongMCatanaCOhrenJPerrinLAEdmundsJJ.Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorgan Med Chem Lett2013;
23:1051–5
157.
PaolinoMChoidasAWallnerSPranjicBUribesalgoILoeserSJamiesonAMLangdonWYIkedaFFededaJPCroninSJNitschRSchultz-FademrechtCEickhoffJMenningerSUngerATorkaRGruberTHinterleitnerRBaierGWolfDUllrichAKleblBMPenningerJM.The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature2014;
507:508–12
158.
SchroederGMAnYCaiZWChenXTClarkCCorneliusLADaiJGullo-BrownJGuptaAHenleyBHuntJTJeyaseelanRKamathAKimKLippyJLombardoLJManneVOppenheimerSSackJSSchmidtRJShenGStefanskiKTokarskiJSTrainorGLWautletBSWeiDWilliamsDKZhangYZhangYFargnoliJBorzilleriRM.Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl) -2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem2009;
52:1251–4
159.
DaiYSiemannDW.BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther2010;
9:1554–61
160.
SharmaSYaoHPZhouYQZhouJZhangRWangMH.Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. Mol Oncol2014;
8:469–82
161.
PatelPRSunHLiSQShenMKhanJThomasCJDavisMI.Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorg Med Chem Lett2013;
23:4398–403
162.
DaiYSiemannDW.Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer2012;
12:198
163.
DaiYBaeKPampoCSiemannDW.Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis2012;
29:253–61
164.
MollardAWarnerSLCallLTWadeMLBearssJJVermaASharmaSVankayalapatiHBearssDJ.Design, synthesis and biological evaluation of a series of novel Axl kinase inhibitors. ACS Med Chem Lett2011;
2:907–12
165.
ZhangWZhangDStashkoMADeRyckereDHunterDKireevDMileyMJCummingsCLeeMNorris-DrouinJStewartWMSatherSZhouYKirkpatrickGMachiusMJanzenWPEarpHSGrahamDKFryeSVWangX.Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem2013;
56:9683–92
166.
ShiCLiXWangXDingNPingLShiYMiLLaiYSongYZhuJ.The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma. J Hematol Oncol2018;
11:43
167.
ZhangWMcIverALStashkoMADeRyckereDBranchfordBRHunterDKireevDMileyMJNorris-DrouinJStewartWMLeeMSatherSZhouYDi PaolaJAMachiusMJanzenWPEarpHSGrahamDKFryeSVWangX.Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem2013;
56:9693–700
168.
KimJEKimYLiGKimSTKimKParkSHParkJOParkYSLimHYLeeHSohnTSKimKMKangWKLeeJ.MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. Oncotarget2017;
8:105727–34
169.
SuarezRMChevotFCavagninoASaettelNRadvanyiFPiguelSBernard-PierrotIStovenVLegraverendM.Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. Eur J Med Chem2013;
61:2–25
170.
PatwardhanPPIvyKSMusiEde StanchinaESchwartzGK.Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget2016;
7:4093–109
171.
DuWHuangHSorrelleN.BrekkenR A Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight2018;
3:pii: 124184
172.
ZhaoJZhangDZhangWStashkoMADeRyckereDVasileiadiEParkerREHunterDLiuQZhangYNorris-DrouinJLiBDrewryDHKireevDGrahamDKEarpHSFryeSVWangX.Highly selective MERTK inhibitors achieved by a single methyl group. J Med Chem2018;
61:10242–54
173.
DonatoNJ.Imatinib is receptive to a collaboration. Blood2011;
118:4009–10
WangLWLiZSZouDWJinZDGaoJXuGM.Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol2008;
14:7192–8
176.
GoodwinPJPritchardKIEnnisMClemonsMGrahamMFantusIG.Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer2008;
8:501–5
177.
Ben SahraILaurentKLoubatAGiorgetti-PeraldiSColosettiPAubergerPTantiJFLe Marchand-BrustelYBostF.The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene2008;
27:3576–86
178.
HadadSMAppleyardVThompsonAM.Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat2009;
114:391
179.
NairVSreevalsanSBashaRAbdelrahimMAbudayyehARodrigues HoffmanASafeS.Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem2014;
289:27692–701
180.
HonjoSAjaniJAScottAWChenQSkinnerHDStroehleinJJohnsonRLSongS.Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol2014;
45:567–74
181.
Ben SahraIRegazzettiCRobertGLaurentKLe Marchand-BrustelYAubergerPTantiJFGiorgetti-PeraldiSBostF.Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res2011;
71:4366–72
182.
PowellNAKohrtJTFilipskiKJKaufmanMSheehanDEdmundsJEDelaneyAWangYBourbonaisFLeeDYSchwendeFSunFMcConnellPCatanaCChenHOhrenJPerrinLA.Novel and selective spiroindoline-based inhibitors of Sky kinase. Bioorgan Med Chem Lett2012;
22:190–3
183.
ZhuHNaujokasMAFixmanEDTorossianKParkM.Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis. J Biol Chem1994;
269:29943–8
184.
BirchmeierCBirchmeierWGherardiEVande WoudeGF.Met, metastasis, motility and more. Nat Rev Mol Cell Biol2003;
4:915–25
185.
ComoglioPMGiordanoSTrusolinoL.Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov2008;
7:504–16
